Large-cap Consumer Discretionary company Kenvue has moved -1.6% so far today on a volume of 10,081,585, compared to its average of 24,921,322. In contrast, the S&P 500 index moved -0.0%.
Kenvue trades -14.3% away from its average analyst target price of $23.67 per share. The 12 analysts following the stock have set target prices ranging from $20.0 to $27.0, and on average have given Kenvue a rating of buy.
Anyone interested in buying KVUE should be aware of the facts below:
-
Based on its trailing earnings per share of 0.56, Kenvue has a trailing 12 month Price to Earnings (P/E) ratio of 36.2 while the S&P 500 average is None
-
KVUE has a forward P/E ratio of 16.0 based on its forward 12 month price to earnings (EPS) of $1.27 per share
-
The company has a price to earnings growth (PEG) ratio of 11.06 — a number near or below 1 signifying that Kenvue is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 3.57 compared to its sector average of None
-
Kenvue Inc. operates as a consumer health company worldwide.
-
Based in Skillman, the company has 22,200 full time employees and a market cap of $38.84 Billion. Kenvue currently returns an annual dividend yield of 1.0%.